Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10322298 | 0.79 | GABRA1 (0.64) | GABRA1GABRB1ERN1ALDH1A1TYR | |
| SCHEMBL13993252 | 0.79 | GABRA1 (0.61) | GABRA1GABRB1LMNA | |
| SCHEMBL10323657 | 0.77 | ERN1 (0.47) | GABRA1GABRB1ERN1ALDH1A1LMNA | |
| SCHEMBL25768537 | 0.75 | ERN1 (0.47) | ERN1ALDH1A1SMN1; SMN2LMNACYP1A2 | |
| SCHEMBL841601 | 0.75 | GABRA1 (0.52) | GABRA1GABRB1ERN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1670597 | 0.74 | ERN1 (0.52) | GABRA1GABRB1ERN1ALDH1A1TYR | |
| SCHEMBL15264345 | 0.74 | ERN1 (0.47) | GABRA1GABRB1ERN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15815028 | 0.73 | ERN1 (0.51) | ERN1ALDH1A1SMN1; SMN2LMNACYP1A2 | |
| SCHEMBL24012721 | 0.72 | ERN1 (0.44) | ERN1ALDH1A1LMNACYP1A2CYP2C19 | |
| SCHEMBL12957472 | 0.72 | ERN1 (0.53) | ERN1ALDH1A1TYRCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178547-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RFC1, RRP1B, RRBP1 | GABRA1 3736/4885GABRB1 3060/4885ERN1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.